|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5283179A
(en)
|
1990-09-10 |
1994-02-01 |
Promega Corporation |
Luciferase assay method
|
|
ES2103770T3
(es)
|
1990-11-26 |
1997-10-01 |
Akzo Nobel Nv |
Procedimiento de produccion de anticuerpos monoclonales.
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
PE64396A1
(es)
|
1995-01-23 |
1997-01-28 |
Hoffmann La Roche |
Proteina accesoria del receptor de la interleucina 1
|
|
UA71889C2
(uk)
|
1996-04-02 |
2005-01-17 |
Йєда Рісерч Енд Дівелопмент Ко. Лтд. |
Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
US6974682B1
(en)
|
1996-08-26 |
2005-12-13 |
Human Genome Sciences, Inc. |
Soluble interleukin-1 receptor accessory molecule
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
EP0915987A2
(en)
|
1997-04-21 |
1999-05-19 |
Donlar Corporation |
POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
|
|
US6280955B1
(en)
|
1997-12-16 |
2001-08-28 |
Tularik Inc. |
Interleukin-1 receptor accessory proteins, nucleic acids and methods
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US6541225B1
(en)
|
2000-01-26 |
2003-04-01 |
Raven Biotechnologies, Inc. |
Methods and compositions for generating human monoclonal antibodies
|
|
US7449443B2
(en)
|
2000-03-23 |
2008-11-11 |
California Institute Of Technology |
Method for stabilization of proteins using non-natural amino acids
|
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
|
US20030026806A1
(en)
|
2000-10-27 |
2003-02-06 |
Amgen Inc. |
Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
|
|
WO2002064630A2
(en)
|
2000-10-31 |
2002-08-22 |
Immunex Corporation |
Il-1 receptor accessory protein
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
GB2375604A
(en)
*
|
2001-05-18 |
2002-11-20 |
Warner Lambert Co |
Methods for screening using interleukin soluble trimolecular complex
|
|
US20030049255A1
(en)
|
2001-08-07 |
2003-03-13 |
Sims John E. |
Interleukin-1 receptors in the treatment of diseases
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7139665B2
(en)
|
2002-02-27 |
2006-11-21 |
California Institute Of Technology |
Computational method for designing enzymes for incorporation of non natural amino acids into proteins
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
GB0216648D0
(en)
|
2002-07-18 |
2002-08-28 |
Lonza Biologics Plc |
Method of expressing recombinant protein in CHO cells
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
CA2824167C
(en)
|
2002-09-06 |
2018-09-25 |
Amgen Inc. |
Therapeutic human anti-il-1r1 monoclonal antibody
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
CN103540600B
(zh)
|
2003-01-22 |
2017-12-01 |
罗氏格黎卡特股份公司 |
融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
|
|
US20040224893A1
(en)
|
2003-05-06 |
2004-11-11 |
Li-Hsien Wang |
Methods of using IL-1 antagonists to treat neointimal hyperplasia
|
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
|
EP1675620B1
(en)
|
2003-10-09 |
2019-05-08 |
Ambrx, Inc. |
Polymer derivatives
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
CA2554735A1
(en)
|
2004-01-30 |
2005-08-11 |
Peplin Biolipids Pty Ltd |
Therapeutic and carrier molecules
|
|
EP2327724A3
(en)
|
2004-02-02 |
2011-07-27 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
CA2655511C
(en)
|
2005-07-01 |
2017-03-21 |
John Schrader |
Methods of isolating cells and generating monoclonal antibodies
|
|
CA2619298C
(en)
|
2005-08-26 |
2017-07-04 |
Glycart Biotechnology Ag |
Modified antigen binding molecules with altered cell signaling activity
|
|
DK2021463T3
(en)
|
2006-05-19 |
2017-01-16 |
Alder Biopharmaceuticals Inc |
Culture method to obtain a cloned population of antigen-specific B cells
|
|
JP2011515497A
(ja)
|
2008-03-26 |
2011-05-19 |
セレラント セラピューティクス インコーポレイテッド |
骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
|
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
GB2472856B
(en)
|
2009-08-21 |
2012-07-11 |
Cantargia Ab |
IL1-RAP modulators and uses thereof
|
|
WO2011078672A1
(en)
*
|
2009-12-24 |
2011-06-30 |
Prosensa Technologies B.V. |
Molecule for treating an inflammatory disorder
|
|
US10233228B2
(en)
|
2010-04-09 |
2019-03-19 |
Albumedix Ltd |
Albumin derivatives and variants
|
|
PL2400298T3
(pl)
|
2010-05-28 |
2014-01-31 |
Hoffmann La Roche |
Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał
|
|
RU2597831C2
(ru)
|
2011-01-19 |
2016-09-20 |
Кантаргия Аб |
Анти-il1rap антитела и их применение при лечении людей
|
|
SG10201602394QA
(en)
*
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
JP2014519480A
(ja)
|
2011-04-15 |
2014-08-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌で使用される抗ｉｌ−１ｒ１阻害物質
|
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
WO2013023015A2
(en)
|
2011-08-11 |
2013-02-14 |
Albert Einstein College Of Medicine Of Yeshiva University |
Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
|
|
US9090694B2
(en)
*
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
WO2014100772A1
(en)
|
2012-12-21 |
2014-06-26 |
Cellerant Therapeutics, Inc. |
Antibodies that bind membrane-bound il1rap
|
|
US10126304B2
(en)
*
|
2013-01-16 |
2018-11-13 |
George Mason Research Foundation, Inc. |
Binding domain mapping
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US20150315179A1
(en)
|
2014-05-02 |
2015-11-05 |
Torrey Pines Institute For Molecular Studies |
Compounds and methods of treating neurological disorders
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
JP7114460B2
(ja)
|
2015-06-26 |
2022-08-08 |
サノフィ・バイオテクノロジー |
モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
|
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
|
AU2023345467A1
(en)
|
2022-09-21 |
2025-05-08 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|